Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

[1]  Kedar S Vaidya,et al.  Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate , 2020, Molecular Cancer Therapeutics.

[2]  A. Letai,et al.  High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors , 2020, Science Signaling.

[3]  H. Kantarjian,et al.  Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. , 2020, Blood advances.

[4]  J. Leighton,et al.  An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. , 2019, Regulatory toxicology and pharmacology : RTP.

[5]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[6]  R. Bronson,et al.  Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo , 2019, Molecular Cancer Therapeutics.

[7]  R. Tammali,et al.  Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition , 2018, Molecular Cancer Therapeutics.

[8]  David C. Smith,et al.  A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma , 2018, Investigational New Drugs.

[9]  R. Hubert,et al.  Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates. , 2018, Cancer research.

[10]  Kedar S Vaidya,et al.  Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate , 2018, Molecular Cancer Therapeutics.

[11]  D. Stover,et al.  Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia , 2017, Molecular Cancer Therapeutics.

[12]  M. Rebelatto,et al.  Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates , 2017, Clinical Cancer Research.

[13]  G. Mills,et al.  Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo , 2017, npj Breast Cancer.

[14]  S. Bidlingmaier,et al.  Macropinocytosis Exploitation by Cancers and Cancer Therapeutics , 2016, Front. Physiol..

[15]  Hirohito Yamaguchi,et al.  A perspective on anti-EGFR therapies targeting triple-negative breast cancer. , 2016, American journal of cancer research.

[16]  Kedar S Vaidya,et al.  ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope , 2016, Molecular Cancer Therapeutics.

[17]  A. Scott,et al.  Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody , 2015, Molecular Cancer Therapeutics.

[18]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[19]  Eunyoung Kang,et al.  High EGFR gene copy number predicts poor outcome in triple-negative breast cancer , 2014, Modern Pathology.

[20]  V. Karantza,et al.  A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors , 2014, Investigational New Drugs.

[21]  V. Blot,et al.  The New Generation of Antibody Drug Conjugates , 2014 .

[22]  Samir J. Courdy,et al.  Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine , 2013, Current protocols in pharmacology.

[23]  Junjeong Choi,et al.  Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. , 2012, Histology and histopathology.

[24]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[25]  S. Vacher,et al.  Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness , 2012, International journal of cancer.

[26]  L. Mazzucchelli,et al.  Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. , 2012, Histology and histopathology.

[27]  R. Wenstrup,et al.  Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer , 2012, Cancer.

[28]  J. Ballesteros,et al.  Bcl‐2 and BLIMP‐1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful , 2012, Histopathology.

[29]  Tao Qin,et al.  EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray , 2012, Medical Oncology.

[30]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[31]  M. Tabrizi,et al.  Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.

[32]  A. Luini,et al.  Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity , 2009, Breast Cancer Research and Treatment.

[33]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[34]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[35]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[36]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[37]  C. Discafani,et al.  Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. , 2006, International journal of oncology.

[38]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[39]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[40]  P. Frost,et al.  Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts , 2004, Clinical Cancer Research.

[41]  J. Falkenburg,et al.  Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity , 2004, Leukemia.

[42]  M. Hashida,et al.  Disposition Characteristics of Macromolecules in Tumor-Bearing Mice , 1990, Pharmaceutical Research.

[43]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[45]  G. Karanikas,et al.  Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: in vivo and in vitro studies. , 2002, Oncology reports.

[46]  A. Ashworth,et al.  Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences , 2001, The EMBO journal.

[47]  R. Weichselbaum,et al.  The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.

[48]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[49]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.